What is RT10?
Triple-receptor incretin agonist profile for metabolic research. The LPPEPTIDE knowledge record describes Retatrutide as an investigational GLP-1, GIP, and glucagon receptor agonist studied in obesity and type 2 diabetes models, with phase II research reporting high-dose body-weight reduction up to 24% over 48 weeks. Retatrutide 10mg is mapped to LPPeptide SKU RT10. Current storefront values use our product data: 10mg x 10 vials /box, $80.00 USD per box. LPPeptide reference specs: 5mg x 10 vials / 10mg x 10 vials / 15mg x 10 vials / 20mg x 10 vials / 30mg x 10 vials / 40mg x 10 vials / 60mg x 10 vials.
Research context
The LPPEPTIDE knowledge record describes Retatrutide as an investigational GLP-1, GIP, and glucagon receptor agonist studied in obesity and type 2 diabetes models, with phase II research reporting high-dose body-weight reduction up to 24% over 48 weeks. Research typically centers on GLP-1, GIP, and glucagon receptor signaling, with endpoints such as appetite signaling, glucose handling, and energy balance models.
Commonly matched with
RT10 is commonly reviewed alongside RT20, RT30, TR10, TR20, Tirzepatide. Keep each combination tied to a defined research objective and lot record.
Compliance notice
RT10 is supplied for research use only. It is not for human or veterinary use, not for consumption, and statements on this page are reference context rather than medical claims.
AGORESEARCH
